Bosutinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 843 publications
Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity.
Journal: Cureus
Published: May 06, 2026
A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.
Journal: medRxiv : the preprint server for health sciences
Published: May 04, 2026
Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137.
Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026
A CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy
Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology
Published: April 27, 2026
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.
Journal: Cancers
Published: April 08, 2026
Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.
Journal: Future science OA
Published: April 04, 2026
Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma.
Journal: Journal of Cancer
Published: March 20, 2026
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.
Journal: Cancer medicine
Published: March 20, 2026
Bosutinib-induced palmoplantar keratoderma treated with acitretin.
Journal: JAAD case reports
Published: March 09, 2026
Key points in selecting first-line therapy for chronic myeloid leukemia
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 04, 2026
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.
Journal: Circulation
Published: February 12, 2026
Intramolecular Interactions of Twenty-Eight Amide Derivatives with the C-ALB Kinase using a Theoretical Model as a Therapeutic Alternative to Treat Cancer.
Journal: Drug research
Published: February 03, 2026
Last Updated: 06/30/2026